---

---

tags : Cancer    entities : Seagen inc.   

save search

---

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
Published: 2024-03-11 (Crawled : 03:00) - prnewswire.com
SGEN | $228.74 0.1% 20M |

Health Technology

| Email alert Add to watchlist
rc48 presentation cancer

---

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
SGEN | $228.74 0.1% 20M |

Health Technology

| 5.98% | O: 0.09% H: 0.0% C: 0.0%
tukysa breast cancer

---

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -19.29% | O: 3.87% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -22.12% | O: -3.37% H: 4.51% C: 4.51%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -13.78% | O: -4.92% H: 1.48% C: -0.21%
padcev fda license review bladder cancer treatment application grants

---

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2023-11-03 (Crawled : 17:00) - biospace.com/
SGEN | $228.74 0.1% 20M |

Health Technology

| 6.49% | O: 0.02% H: 0.0% C: 0.0%
cd30 adcetris cancer tumor preclinical immunotherapy meeting

---

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| Email alert Add to watchlist
SGEN | $228.74 0.1% 20M |

Health Technology

| Email alert Add to watchlist
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| Email alert Add to watchlist
ev-302 padcev bladder cancer trial

---

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
Published: 2023-10-22 (Crawled : 16:20) - globenewswire.com
GMAB | News | $28.47 -0.32% -0.32% 420 |

Health Technology

| Email alert Add to watchlist
SGEN | $228.74 0.1% 20M |

Health Technology

| Email alert Add to watchlist
GNMSF | News | $290.34 0.23% 3.83% 0 |

Health Technology

| Email alert Add to watchlist
tivdak cancer global trial

---

Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
Published: 2023-10-20 (Crawled : 14:30) - prnewswire.com
SGEN | $228.74 0.1% 20M |

Health Technology

| 6.41% | O: 0.15% H: 0.0% C: 0.0%
ONCY | $1.05 -0.94% -3.35% 1.5K |

Health Technology

| -32.1% | O: -1.85% H: 3.14% C: -2.52%
MYGN | $18.63 0.16% 0.05% 480K |

Health Technology

| 27.08% | O: 0.41% H: 3.13% C: 2.38%
ILMN | $122.87 -1.28% -1.4% 330 |

Health Technology

| 2.41% | O: 0.02% H: 0.94% C: -0.3%
BNTX | News | $88.09 -0.45% -0.35% 1.9K |

Health Technology

| -5.52% | O: -1.46% H: 0.48% C: -1.06%
companies biotech cancer pancreatic treatment research

---

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Published: 2023-09-22 (Crawled : 09:00) - prnewswire.com
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -33.82% | O: -0.56% H: 1.48% C: 1.12%
SGEN | $228.74 0.1% 20M |

Health Technology

| 10.83% | O: 3.59% H: 0.09% C: -0.05%
ev-302 padcev bladder cancer trial

---

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics
Published: 2023-09-07 (Crawled : 11:00) - globenewswire.com
SGEN | $228.74 0.1% 20M |

Health Technology

| 10.34% | O: -0.55% H: 0.2% C: -0.62%
NRIX 6 d | $13.75 -2.69% -2.91% 520K |

Health Technology

| 67.89% | O: 8.91% H: 6.28% C: 0.67%
cancer protein collaboration therapeutics

---

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
Published: 2023-09-04 (Crawled : 19:00) - globenewswire.com
GNMSF | News | $290.34 0.23% 3.83% 0 |

Health Technology

| -27.27% | O: 0.46% H: 0.0% C: -2.28%
ZLAB | $15.66 3.57% 3.45% 430K |

Health Technology

| -40.0% | O: 11.76% H: 1.61% C: -1.82%
SGEN | $228.74 0.1% 20M |

Health Technology

| 8.72% | O: -1.07% H: 0.02% C: -0.47%
GMAB | News | $28.47 -0.32% -0.32% 420 |

Health Technology

| -25.82% | O: 0.57% H: 0.0% C: -1.55%
tivdak cancer

---

Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Published: 2023-08-16 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M |

Health Technology

| 17.79% | O: -0.02% H: 0.39% C: -0.42%
tukysa breast cancer trial

---

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer
Published: 2023-06-05 (Crawled : 13:00) - prnewswire.com
SGEN | $228.74 0.1% 20M |

Health Technology

| 17.07% | O: -0.36% H: 0.76% C: 0.26%
asco bladder cancer results

---

Non-hodgkin lymphoma therapeutics market size to increase by USD 5,427.51 million between 2022 and 2027; Growing awareness about cancer as a key trend - Technavio
Published: 2023-03-24 (Crawled : 19:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M |

Health Technology

| Email alert Add to watchlist
AZNCF | News | $135.35 -3.53% -4.19% 0 |

Health Technology

| Email alert Add to watchlist
BIIB | $201.99 4.56% 4.32% 420 |

Health Technology

| Email alert Add to watchlist
BAX | $40.93 -0.22% 0.0% 3 |

Health Technology

| Email alert Add to watchlist
GSK | News | $40.86 -0.92% 0.91% 11K |

Health Technology

| Email alert Add to watchlist
GLAXF | News | $19.54 -3.77% -14.18% 0 |

Health Technology

| Email alert Add to watchlist
TEVJF | News | $12.37 -24.22% 380 |

Health Technology

| Email alert Add to watchlist
NVSEF | News | $96.0 0.94% 6.88% 0 |

Health Technology

| Email alert Add to watchlist
SGEN | $228.74 0.1% 20M |

Health Technology

| Email alert Add to watchlist
AZN | News | $71.2 0.49% 0.46% 300K |

Health Technology

| Email alert Add to watchlist
cancer growing therapeutics market

---

Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
Published: 2023-03-14 (Crawled : 23:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 0 |

Health Technology

| -1.98% | O: -1.13% H: 0.0% C: -0.22%
SGEN | $228.74 0.1% 20M |

Health Technology

| 15.73% | O: 0.68% H: 0.55% C: 0.42%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| 0.14% | O: -0.08% H: 0.0% C: 0.0%
preclinical meeting therapeutics cancer

---

Pfizer Invests $43 Billion to Battle Cancer
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -33.31% | O: -0.34% H: 3.18% C: 1.54%
SGEN | $228.74 0.1% 20M |

Health Technology

| 32.52% | O: 15.14% H: 2.07% C: -0.55%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| -0.67% | O: -0.81% H: 0.0% C: 0.0%
cancer

---

Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
Published: 2023-03-09 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -32.31% | O: 0.32% H: 0.46% C: -0.32%
SGEN | $228.74 0.1% 20M |

Health Technology

| 31.73% | O: 0.0% H: 0.2% C: -0.59%
medical application license cancer

---

Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
Published: 2023-02-13 (Crawled : 23:00) - biospace.com/
SGEN | $228.74 0.1% 20M |

Health Technology

| 68.92% | O: -0.35% H: 3.01% C: 2.93%
research symposium cancer

---

Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Published: 2023-01-19 (Crawled : 00:00) - biospace.com/
SGEN | $228.74 0.1% 20M |

Health Technology

| 75.29% | O: 0.55% H: 1.94% C: 0.6%
tukysa fda approval cancer her2- her2

---

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:20) - biospace.com/
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -38.31% | O: 1.66% H: 1.12% C: 0.03%
MRK | $127.0 0.1% 2.37% 62K |

Health Technology

| 16.05% | O: 0.46% H: 0.65% C: -0.21%
SGEN | $228.74 0.1% 20M |

Health Technology

| 79.22% | O: 0.0% H: 4.57% C: 4.22%
padcev treatment fda cancer

---

Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:00) - prnewswire.com
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -38.31% | O: 1.66% H: 1.12% C: 0.03%
MRK | $127.0 0.1% 2.37% 62K |

Health Technology

| 16.05% | O: 0.46% H: 0.65% C: -0.21%
SGEN | $228.74 0.1% 20M |

Health Technology

| 79.22% | O: 0.0% H: 4.57% C: 4.22%
padcev treatment fda license cancer

---

Gainers vs Losers

61%

39%

Top 10 Gainers

BOF | $2.08 77.78% 39.06% 110M |

BHIL | $0.1793 -4.37% 19.24% 340K |

Agriculture, Forestry, Fishing ...

UMAC | $1.48 -1.33% 14.87% 20K |

CI | $352.28 -0.11% 13.53% 2 |

Health Services

CIG.C | $2.89 -1.37% 12.8% 2.3K |

n/a

BMTX 4 | $1.545 0.98% 10.03% 2.5K |

Information

TAL | $12.26 0.57% 9.22% 12M |

Consumer Services

MTH | $154.69 -2.21% 7.56% 64 |

Consumer Durables

ASXC | $0.243 -2.41% 7.0% 1.1M |

Manufacturing

IHT P | $1.3712 0.82% 6.48% 0 |

Finance

---

Your saved searches

---